Israel has agreed to give the first 5,000 vaccine doses to Palestinian medical workers - but only if they live in annexed east Jerusalem, while the West Bank and Gaza remain without vaccines.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.
A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.
Prime Minister Boris Johnson announced that he had done "everything possible" to prevent 100,000 COVID deaths, as the UK witnesses 50,099 fatalities in the space of 79 days.
New vaccine data from Israel suggests that the double-dose of Pfizer is performing at the expected rate of 95% efficiency - with the possibility that it is performing even better than that being further investigated.
In response to the AstraZeneca feud, EU officials are creating a "transparency mechanism" for vaccine exports - which would indirectly hold companies accountable for fulfilling their agreed contracts.
